Filing Flows › Generate Biomedicines (GENB) › Q2 2026
Generate Biomedicines (GENB) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Generate Biomedicines (GENB) reported revenue of $6.3M for the second quarter 2026 (Q2 2026), -38% from a year earlier and -13% from the quarter before.
Generate Biomedicines, Q2 2026: revenue $6.3M (-38% year over year), net loss $67.3M, operating cash flow −$57.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.3M | -13% | -38% |
| Operating profit | −$71.6M | — | — |
| Net earnings | −$67.3M | — | — |
| Operating cash flow | −$57.9M | — | — |
What changed
Revenue was $6.3M in Q2 2026, down 38% year over year and down 13% from the previous quarter.
Operating costs exceeded revenue by $71.6M, an operating margin of -1134.2%. Total costs grew 11% against a revenue fall of 38%. The fastest-growing cost line was General & admin (+29%). The quarter ended with a net loss of $67.3M, wider than the previous quarter's $61.7M loss.
Operating cash flow was −$57.9M. Non-cash charges added back $3.2M of depreciation and amortization and $8.2M of share-based compensation. Capital expenditures of $933K exceeded it, leaving free cash flow of −$58.9M.
Questions
What was Generate Biomedicines' revenue in the second quarter 2026?
Generate Biomedicines (GENB) reported revenue of $6.3M for the second quarter 2026 (Q2 2026), -38% from a year earlier and -13% from the quarter before.